Dr Jan Burger speaks with ecancertv at BSH 2016 reports on the results of the RESONATE2 trial in CLL patients.

RESONATE2 was a comparative trial, assessing response rates of patients receiving traditional therapies compared to those receiving ibrutinib, a novel BTK inhibitor.

The results favour ibrutinib as a frontline treatment, with prolonged patient survival and a lower toxicity profile, and follow from results gained in the previous RESONATE trial.

Ibrutinib is now approved for treatment in the US, and has just received positive opinion in Europe for expanded use in previously untreated CLL patients

For more from Dr Burger on CLL, you can watch another interview with him describing crosstalk between leukaemia cells and the tumour microenvironment here.

ecancer's filming at ICMM 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.